Abstract
We have reviewed the experience in a single center of a biologic register for rheumatoid arthritis patients. Over the past decade, the entry demographics show that we are treating patients at an earlier stage and with slightly less severe disease. Our outcomes measured by the percentage in DAS28 remission are comparable with national databases. We were surprised by the small number who were switched from their first biologic to a second (27 %), but this might reflect the lack of a firm “treat to target” approach. Our use of concomitant methotrexate/leflunomide is less than we would have liked and thought, but our use of concomitant corticosteroids is much less than normally seen. A single-center registry can provide useful monitoring and quality assurance data and stimulate change.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Maksymowych WP, Ohinmaa A, Martin L, Russell AS et al (2010) Primary anti-TNF failures experience better clinical responses but similar health care utilization to a second anti-TNF agent than secondary failures: analysis of the Alberta RA biologics registry. Arthritis Rheum 62:S138
De Punder YMR, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MAFJ, van Riel PLCM (2012) The prevalence of clinical remission in rheumatoid arthritis patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) Registry. Rheumatology 51:1610–1617
Kingsley G, Scott IC (2011) Quality of life and the outcome of established rheumatoid arthritis. Best Pract Res Cl Rh 25:585–606
Iannone F, Gremese E, Atzeni F, Biasi D, Botsios C, Cipriani P et al (2012) Long-term retention of tumor necrosis factor-α inhibitor therapy in a large Italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. J Rheumatol 39(6):1179–1184
Inotai A, Rojkovich B, Fulop A, Jaszay E, Agh T, Meszaros A (2012) Health related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. Rheumatol Int 32:963–969
Gulfe A, Kristensen LE, Saxne T, Jacobsson LTH, Petersson IF, Geborek P (2010) Utility-based outcomes made easy: the number needed per quality-adjusted life year gained. An observational cohort study of tumor necrosis factor blockade in inflammatory arthritis from Southern Sweden. Arthritis Care Res 62:1399–1406
Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL, British Society for Rheumatology Biologics Register (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:583–589
Choquette D (2012) Lower than expected levels of DMARD acquisition immediately pre and post biologic initiation in RA patients. Ann Rheum Dis 71(Suppl 3):668
Dixon WG, Suissa S, Hudson M (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 13:R139
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Russell, A.S., Mallon, C., Conner-Spady, B. et al. A biologic pharmacosurveillance program for rheumatoid arthritis: a single-center experience. Clin Rheumatol 32, 875–877 (2013). https://doi.org/10.1007/s10067-013-2177-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-013-2177-7